Preclinical biodistribution and dosimetry and human biodistribution comparing
18F
Biodistribution
Dosimetry
PET/CT
PSMA
rhPSMA
Journal
EJNMMI research
ISSN: 2191-219X
Titre abrégé: EJNMMI Res
Pays: Germany
ID NLM: 101560946
Informations de publication
Date de publication:
04 Feb 2022
04 Feb 2022
Historique:
received:
02
07
2021
accepted:
06
12
2021
entrez:
4
2
2022
pubmed:
5
2
2022
medline:
5
2
2022
Statut:
epublish
Résumé
Radiohybrid prostate-specific membrane antigen (rhPSMA) ligands such as Preclinical dosimetry was performed with SCID-mice sacrificed at multiple timepoints (10-300 min) post-injection of 25.6 ± 3.6 MBq Preclinical dosimetry revealed that at 3.5 h and 1 h bladder voiding intervals, the extrapolated total effective doses were 26.6 and 12.2 µSv/MBq for Radiation dosimetry is favourable for both agents. Radiation exposure, assuming a 1 h voiding interval, is less than 5 mSv after injection of 370 MBq.
Sections du résumé
BACKGROUND
BACKGROUND
Radiohybrid prostate-specific membrane antigen (rhPSMA) ligands such as
METHODS
METHODS
Preclinical dosimetry was performed with SCID-mice sacrificed at multiple timepoints (10-300 min) post-injection of 25.6 ± 3.6 MBq
RESULTS
RESULTS
Preclinical dosimetry revealed that at 3.5 h and 1 h bladder voiding intervals, the extrapolated total effective doses were 26.6 and 12.2 µSv/MBq for
CONCLUSIONS
CONCLUSIONS
Radiation dosimetry is favourable for both agents. Radiation exposure, assuming a 1 h voiding interval, is less than 5 mSv after injection of 370 MBq.
Identifiants
pubmed: 35119557
doi: 10.1186/s13550-021-00872-w
pii: 10.1186/s13550-021-00872-w
pmc: PMC8816989
doi:
Types de publication
Journal Article
Langues
eng
Pagination
8Informations de copyright
© 2022. The Author(s).
Références
J Nucl Med. 2020 May;61(5):710-715
pubmed: 31836681
Mol Imaging Biol. 2015 Aug;17(4):565-74
pubmed: 25896814
J Nucl Med. 1973 Sep;14(9):713-7
pubmed: 4724345
J Nucl Med. 2012 Dec;53(12):1883-91
pubmed: 23203246
J Pharm Sci. 1993 Jul;82(7):761-3
pubmed: 8360854
Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):1014-1024
pubmed: 28283702
Eur J Nucl Med Mol Imaging. 2017 Apr;44(4):678-688
pubmed: 27889802
PLoS One. 2017 Aug 17;12(8):e0183329
pubmed: 28817656
Cancer. 1998 Jun 1;82(11):2256-61
pubmed: 9610707
J Nucl Med. 2020 May;61(5):735-742
pubmed: 31862804
EJNMMI Res. 2020 Dec 7;10(1):149
pubmed: 33284394
J Cell Biochem. 2004 Feb 15;91(3):528-39
pubmed: 14755683
J Nucl Med. 2020 May;61(5):702-709
pubmed: 31836686
J Nucl Med. 2020 May;61(5):696-701
pubmed: 31836682
Proc Natl Acad Sci U S A. 2011 Jun 7;108(23):9578-82
pubmed: 21606347
J Nucl Med. 2005 Jun;46(6):1023-7
pubmed: 15937315
J Nucl Med. 2021 May 10;62(5):679-684
pubmed: 33067338